Altimmune(US:ALT)2026-03-05 14:30Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024, indicating an increase in losses year-over-year [31] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the completion of the Phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by a one-time charge related to executive transition and increased professional fees [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from Phase 2 trials showing early MASH resolution and anti-fibrotic activity [8][14] - The Phase 2 MASH study demonstrated significant improvements in liver fat content and liver health markers, with a favorable tolerability profile leading to low discontinuation rates [16][17] Market Data and Key Metrics Changes - Market research indicated a high unmet need for therapies addressing tolerability issues in MASH patients, with many physicians recognizing the limitations of current therapies [24][25] - Over 70% of healthcare professionals surveyed expressed a high likelihood to prescribe pemvidutide, indicating strong market interest [27] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and late-stage clinical development [10] - The Phase 3 trial for pemvidutide is set to begin this year, with a focus on addressing both hepatic and metabolic drivers of MASH [19][20] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide, especially after receiving FDA Breakthrough Therapy designation, which could facilitate its approval process [9] - The company is preparing for the Phase 3 trial while also executing well on other Phase 2 trials, indicating a robust pipeline and commitment to addressing liver diseases [12][20] Other Important Information - The company raised $75 million in a capital raise in January 2026, enhancing its financial position to support ongoing clinical programs [11][33] - The total cash position at year-end 2025 was reported at $274 million, with a pro forma cash position of approximately $340 million after recent funding [33] Q&A Session Summary Question: Can you provide insights on the Phase 3 trial and potential cost savings? - Management clarified that the FDA's new pivotal framework does not directly apply to their approach, and they are focused on a single trial for accelerated approval [38] Question: What are the statistical plans for the Phase 3 trial? - The Phase 3 trial is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [41] Question: What is the FDA's stance on using NIT as a registrational endpoint? - The FDA indicated it was premature to consider NITs as registrational endpoints, but the company is capturing all relevant data [49] Question: What are the key elements locked in for the Phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, focusing on comprehensive biopsy processes [87] Question: How will the company approach the AUD and ALD trials? - The company plans to assess the AUD trial data upon receipt and will not wait for ALD data before determining next steps [94]